Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Asymchem Laboratories Tianjin Co Cash-to-Debt?
Asymchem Laboratories Tianjin CoASLTY 69 Cash-to-Debt is 26.54 as of Mar. 2026, which is 57% below its 10-year median of 62.17. GuruFocus rates ASLTY with a GF Score™ of 69/100 and a GF Value™ of $4.92 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,400 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks better than 65.71% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Asymchem Laboratories Tianjin Co's cash to debt ratio for the quarter that ended in Mar. 2026 was 26.54.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Asymchem Laboratories Tianjin Cocould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's Cash-to-Debt or its related term are showing as below:
ASLTY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.75 Med: 62.17 Max: No Debt
Current: 26.54
During the past 13 years, Asymchem Laboratories Tianjin Co's highest Cash to Debt Ratio was No Debt. The lowest was 2.75. And the median was 62.17.
ASLTY's Cash-to-Debt is ranked better than 65.71% of 1400
companies
in the Biotechnology industry
Industry Median: 6.52
vs ASLTY: 26.54
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Asymchem Laboratories Tianjin Co Cash-to-Debt Related Terms
Asymchem Laboratories Tianjin Co Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Asymchem Laboratories Tianjin Co Cash-to-Debt Chart
ASLTY vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a Cash-to-Debt of 26.54 as of Mar. 2026. This is 57% below median its historical median of 62.17. Over the past decade, Asymchem Laboratories Tianjin Co's Cash-to-Debt has ranged from 2.75 to 10,000.00. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #480 out of 1400 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Asymchem Laboratories Tianjin Co's Cash-to-Debt too high?
Asymchem Laboratories Tianjin Co's current Cash-to-Debt of 26.54 is 57% below median its 10-year median of 62.17. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.52. Asymchem Laboratories Tianjin Co's value of 26.54 is 307.1% above this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #480 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #480 out of 1400 companies for Cash-to-Debt. This puts Asymchem Laboratories Tianjin Co in the upper half of its industry. The industry median Cash-to-Debt is 6.52. Asymchem Laboratories Tianjin Co's value of 26.54 is 307.1% above this benchmark. Historically, Asymchem Laboratories Tianjin Co's own Cash-to-Debt has ranged from 2.75 to 10,000.00 over the past decade. While the company's 10-year median is 62.17 vs. the industry median of 6.52, Asymchem Laboratories Tianjin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.52, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Cash-to-Debt of 26.54 is 307.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Cash-to-Debt is 26.54, which is 57% below median its own 10-year median of 62.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.92, compared to a current price of $7.45 — trading 51.4% above its estimated fair value. The current Cash-to-Debt is 26.54, which is 57% below median its 10-year median of 62.17 and 307.1% above the Biotechnology industry median of 6.52. Asymchem Laboratories Tianjin Co's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Cash-to-Debt is 26.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $7.45 is trading 51.4% above its estimated GF Value™ of $4.92.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Cash-to-Debt: 26.54 (57% below median its 10-year median of 62.17)
GF Value™: $4.92 vs. price of $7.45 (51.4% above fair value)
Industry Position: 307.1% above the Biotechnology median (#480 of 1400)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
69GF Score
Get the complete analysis for ASLTY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
